Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2016

View Archived Issues

FDA grants orphan drug designation to JCAR-017

University of Ljubljana discloses BChE inhibitors

Cocrystal Pharma introduces NS5B inhibitors

Combination of FLT3 inhibitor and homoharringtonine shows promise in FLT3-ITD acute myeloid leukemia

Merck & Co. patents HIV integrase inhibitors

GlaxoSmithKline discovers BET inhibitors

Crescendo and Takeda enter global collaboration for Humabody-based therapeutics

Taisho Pharmaceutical reports compounds useful for RSV infection

Piramal Enterprises to acquire Janssens injectable anesthesia and pain management products

Apta-1 demonstrates great potential in preclinical studies

Meiji Seika opens phase I pharmacokinetic bioequivalence study of DMB-3113 and adalimumab in Japan

LY-3023414 and necitumumab combination appears safe in non-small cell lung cancer

Cellceutix reports early positive results for brilacidin trial

Signs of efficacy seen with anti-PD-1 monoclonal antibody MEDI-0680 in phase I trial

Xenetic Biosciences reports positive data from phase II trial of erepoxen

Nordic Nanovector enters collaboration with Legochem Bioscience for leukemia research

FDA grants priority review to Lucentis sBLA for myopic CNV

Kymab and EpimAb sign bispecific antibody cross-licensing agreement

NIH grant supports work at OHSU in Fanconi's anemia

3SBio announces commercialization license agreement for Byetta and Bydureon in China

Addex initiates study of ADX-88178 in nonhuman primate model of cocaine addiction

First-in-human study finds FGFR inhibitor BAY-1163877 is well tolerated

FDA grants breakthrough therapy designation to Gamida Cell's NiCord

Disease control seen in first-in-human trial of NVP-CGM-097 in advanced solid tumors

Milestone in USP partnership between Hybrigenics and Servier

Nusinersen MAA submitted to EMA

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...